High levels of retinal docosahexaenoic acid do not protect photoreceptor degeneration in VPP transgenic mice.
OBJECTIVE
To determine whether docosahexaenoic acid can protect against hereditary retinal degenerations in transgenic mice expressing the V20G, P23H, and P27L (VPP) rhodopsin mutations.


METHODS
Female transgenic mice expressing the VPP rhodopsin mutation, known to cause a retinal degeneration, were bred to male transgenic mice expressing the fat-1 gene, which can convert n6 to n3 polyunsaturated fatty acids (PUFA). Several weeks before breeding, the female mice were fed a standard diet containing 10% safflower oil (SFO), which is high in n6 and low in n3 PUFA (n6/n3=273). Offspring were genotyped and four groups identified: Fat1(+)/VPP(+), Fat1(-)/VPP(+), Fat1(+)/VPP(-), and Fat1(-)/VPP(-). Dams were maintained on the SFO diet during the nursing period and offspring were kept on the SFO diet after weaning. At 4, 16, and 28 weeks of age, retinal function was evaluated by electroretinography (ERG), photoreceptor cell loss was quantified by measuring outer nuclear layer thickness, and rhodopsin levels were determined. Fatty acid profiles were analyzed in whole retina, plasma, and liver at 4 and 28 weeks of age.


RESULTS
Expression of fat-1 in the absence of dietary n3 PUFA led to the generation of two groups of mice with distinctly different levels of n3 and n6 PUFA in the three tissues that were analyzed. Already at four weeks of age, the retinas of fat-1 positive animals had higher levels of n3 PUFA than their wild-type counterparts (23%-29% versus 6.4%-6.5%). In addition, by four weeks of age, there was a significant loss of rod photoreceptor cells in the VPP mice. Progression of retinal degeneration occurred with increasing age in VPP positive mice, with photoreceptor cell death occurring in both inferior and superior regions. Amplitudes of the a- and b-waves of the ERG were significantly reduced with age, with VPP positive mice showing the greatest change. Rhodopsin content was lower in the VPP transgenic mice. There were no significant differences in outer nuclear layer thickness or ERG amplitudes between Fat1(+)/VPP(+) and Fat1(-)/VPP(+), or between Fat1(+)/VPP(-)and Fat1(-)/VPP(-) mice at any of the three ages.


CONCLUSIONS
High levels of retinal docosahexaenoic acid do not protect mice expressing the VPP rhodopsin mutation from retinal degeneration.
Li
Feng
F
Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Marchette
Lea D
LD
Brush
Richard S
RS
Elliott
Michael H
MH
Davis
Kimberly R
KR
Anderson
Ashley G
AG
Anderson
Robert E
RE
D000818:Animals; D004281:Docosahexaenoic Acids / Q000378:metabolism*; D004596:Electroretinography; D005227:Fatty Acids / Q000097:blood / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics*; D020419:Photoreceptor Cells, Vertebrate / Q000378:metabolism / Q000473:pathology; D012160:Retina / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D012162:Retinal Degeneration / Q000378:metabolism* / Q000503:physiopathology; D012243:Rhodopsin / Q000235:genetics* / Q000378:metabolism
D005227:Fatty Acids; D004281:Docosahexaenoic Acids; D012243:Rhodopsin
Proc Natl Acad Sci U S A. 1986 Jun;83(11):4021-5
3459166
Science. 1973 Dec 21;182(4118):1253-4
4752217
Pediatr Res. 1990 Nov;28(5):485-92
2255573
Biochem Biophys Res Commun. 1986 Dec 15;141(2):600-4
2948509
Arch Ophthalmol. 2004 Sep;122(9):1306-14
15364709
Exp Eye Res. 1994 Feb;58(2):129-37
8157107
Mol Vis. 2004 Mar 26;10:199-207
15064683
Invest Ophthalmol Vis Sci. 1992 Oct;33(11):3242-53
1399429
Exp Eye Res. 1997 Feb;64(2):181-7
9176051
Neuroscience. 1998 Dec;87(3):709-17
9758235
J Neurochem. 1991 Nov;57(5):1690-9
1833510
J Opt Soc Am A Opt Image Sci Vis. 1996 Mar;13(3):577-85
8627415
Exp Eye Res. 1991 Dec;53(6):741-52
1838336
Invest Ophthalmol Vis Sci. 1992 Jul;33(8):2365-76
1386065
Exp Eye Res. 1991 Mar;52(3):349-55
1826654
Exp Eye Res. 1993 Sep;57(3):359-68
8224023
Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):263-7
18042365
Invest Ophthalmol Vis Sci. 1999 May;40(6):1040-9
10235537
Am J Ophthalmol. 2004 Apr;137(4):704-18
15059710
Science. 1975 Jun 27;188(4195):1312-4
1145197
Arch Ophthalmol. 2004 Sep;122(9):1297-305
15364708
Mol Vis. 2009 Jun 13;15:1185-93
19536303
Mol Vis. 2005 May 12;11:338-46
15928607
J Nutr. 1989 Dec;119(12):1880-92
2576038
J Neurosci. 1996 Dec 15;16(24):7853-8
8987813
J Clin Invest. 1984 Jan;73(1):272-6
6317716
Invest Ophthalmol Vis Sci. 1992 Aug;33(9):2596-602
1386350
J Lipid Res. 2009 Apr;50 Suppl:S400-5
19018037
Exp Eye Res. 1991 Sep;53(3):415-7
1936178
J Lipid Res. 1995 Jul;36(7):1427-33
7595066
Invest Ophthalmol Vis Sci. 1995 May;36(6):1009-18
7730010
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5499-503
8516292
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5445-53
18055791
World Rev Nutr Diet. 1998;83:52-60
9648504
Trans Ophthalmol Soc U K. 1983;103 ( Pt 5):508-12
6591588
J Lipid Res. 2009 May;50(5):807-19
19023138
Prog Lipid Res. 1983;22(2):79-131
6348799
Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2164-6
9761296
Nature. 1990 Jan 25;343(6256):364-6
2137202
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1142-7
9037020
J Biol Chem. 2004 Jul 23;279(30):31098-104
15145938
Exp Eye Res. 1987 Jan;44(1):155-9
2951269
J Neurosci. 2004 Jun 23;24(25):5651-8
15215287
Nature. 2004 Feb 5;427(6974):504
14765186
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1715-20
11431433
Mol Vis. 2002 Sep 23;8:351-8
12355064
Invest Ophthalmol Vis Sci. 1997 Oct;38(11):2387-407
9344362